UBS lowered the firm’s price target on Neurocrine (NBIX) to $178 from $188 and keeps a Buy rating on the shares. Crenessity momentum could break the stock out of its historical range, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Ingrezza capsules show efficacy in involuntary movement disorders
- Neurocrine price target lowered to $177 from $179 at JPMorgan
- Neurocrine price target lowered to $169 from $172 at Truist
- Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley
- RBC Capital would be a buyer of Neurocrine on weakness following competitor data